Bolt Biotherapeutics Q1 2023 net loss $18.4M; cash $171M; BDC-1001 Phase 2 plans

Bolt Biotherapeutics, Inc.

2023-Q1 EPS reported -$0.45 revenue$1,826,000

Net loss from operations $18.4M vs $23.9M in Q1 2022; collaboration revenue $1.8M (up from $0.8M).
Cash, equivalents, and marketable securities $171.0M as of March 31, 2023; expected to fund operations through 2025.
R&D expenses $14.6M (down from $18.4M) due to lower manufacturing and pipeline reprioritization.
BDC-1001 Phase 2 program to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer.
Comprehensive BDC-1001 safety/efficacy data to be presented at ASCO 2023 on June 3.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bolt Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.